Redsense Q1 net sales rise, helped by higher usage

About this update from Redsense Medical Ab

OverviewBlood leakage monitor maker's Q1 net sales rose yr/yr, company returned to profitCompany attributes growth to increased usage and broader adoption of installed systemsFirst Clamp System sale completed in UK clinic during Q1OutlookCompany aims to increase end-customer usage in the U.S. and expand into new markets in 2026Redsense plans to progress rollout of the Clamp and support broader adoption in 2026Company expects stronger operational base and commercial approach to support continued growthResult DriversINCREASED USAGE - Co said higher sales of disposables indicated increased usage of previously installed systems and strengthened underlying demandREVISED PRICING STRUCTURE - Co said new U.S. pricing, with lower per-treatment consumable cost, supported broader adoption and contributed to higher usageINVENTORY PRICING RECONCILIATION - Part of Q1 sales increase reflected a reconciliation of pricing on existing U.S. inventory ahead of the changeCompany press release:Key DetailsMetricBeat/MissActualConsensus EstimateQ1 SalesSEK 6.40 mlnQ1 EPSSEK 0.07Q1 Net IncomeSEK 1.12 mlnQ1 EBITSEK 1.08 mlnFor questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

View stock analysis, news, and events for Redsense Medical Ab